It is not surprising that President Trump issued a May 12, 2025 executive order, “Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients," which represents the administration’s efforts to lower prescription drug prices. This action uses what is known as “most favored nation” pricing to link the price of selected U.S. pharmaceutical drugs in America to countries where the same drugs are sold for less. The order extends beyond Medicare Part B drugs and will likely target lucrative expensive medications like GLP-1 drugs (known for weight management et al). Also targeted will be the ability of Big Pharma to set its own prices.
It is sensible both economically and politically.
Read Full Article »
